查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1824317

2025年全球子宮肌瘤治療市場報告

Uterine Fibroids Treatment Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

子宮肌瘤治療市場規模預計將在未來幾年強勁成長，到2029年將達到64.3億美元，複合年成長率為9.8%。預測期內的成長可歸因於非侵入性治療的進步、對生育力保存的日益重視、微創技術的興起、個人化醫療方法以及合作研發。預測期內的主要趨勢包括：更加重視生育力保存治療、將影像技術融入治療計劃、進行認知和教育活動、根據患者情況量身定做治療方案以及探索新的治療標靶。

未來五年9.8%的成長率預測比我們先前的預測略有下降，下降了0.1%。這一下降主要源自於美國與其他國家之間關稅的影響。關稅上調可能會增加美國患者的負擔，因為這會增加從以色列和加拿大進口的磁振造影引導聚焦超音波設備和孕酮調節劑的成本，從而加劇手術延誤並增加婦科費用。由於互惠關稅以及貿易緊張局勢和限制加劇對全球經濟和貿易的負面影響，關稅上調的影響也可能更加廣泛。

子宮肌瘤治療市場預期成長的原因是女性子宮肌瘤的高發生率。子宮肌瘤是發生在子宮內的非癌症腫瘤，可引起月經過多、骨盆腔疼痛以及膀胱或腸道壓迫等症狀。子宮肌瘤的治療包括抑制雌激素和黃體素的產生，停止月經並改善貧血。例如，根據美國國家生物技術資訊中心2022年11月發布的報告，35歲以下女性子宮肌瘤的發生率估計為40-60%，50歲以上女性子宮肌瘤的發生率估計為70-80%。因此，全球子宮肌瘤的流行正在推動子宮肌瘤治療市場的成長。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通膨、地緣政治、貿易戰和關稅，以及新冠疫情和復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球子宮肌瘤治療：PESTEL分析（政治、社會、技術、環境、法律因素、促進因素與限制因素）
  • 最終用途產業分析
  • 全球子宮肌瘤治療市場：成長率分析
  • 全球子宮肌瘤治療市場表現：規模與成長，2019-2024
  • 全球子宮肌瘤治療市場預測：規模與成長，2024-2029年，2034年
  • 全球子宮肌瘤治療：總目標市場（TAM）

第6章 市場細分

  • 全球子宮肌瘤治療市場：依類型、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 漿膜下肌瘤
  • 子宮壁間肌瘤
  • 黏膜下肌瘤
  • 帶蒂子宮肌瘤
  • 全球子宮肌瘤治療市場（依治療類型、績效及預測），2019-2024 年、2024-2029 年、2034 年
  • 荷爾蒙療法
  • 雄激素
  • 促性腺激素分泌釋放激素拮抗劑
  • 子宮動脈栓塞術
  • 子宮肌瘤切除術
  • 子宮切除術
  • 全球子宮肌瘤治療市場：按最終用戶、績效和預測，2019-2024 年、2024-2029 年、2034 年
  • 醫院
  • 門診手術中心
  • 其他最終用戶
  • 全球子宮肌瘤治療市場：漿膜下肌瘤細分（按類型）、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 帶蒂漿膜下肌瘤
  • 無蒂漿膜下肌瘤
  • 全球子宮肌瘤治療市場：按肌壁內肌瘤（按類型）細分、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 小壁間肌瘤
  • 大型壁間肌瘤
  • 全球子宮肌瘤治療市場：依黏膜下肌瘤類型細分、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 帶蒂粘膜下肌瘤
  • 無蒂黏膜下肌瘤
  • 全球子宮肌瘤治療市場：細分：帶蒂子宮肌瘤（按類型）、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 漿膜下帶蒂子宮肌瘤
  • 黏膜下帶蒂子宮肌瘤

第7章 區域和國家分析

  • 全球子宮肌瘤治療市場：按地區、結果和預測，2019-2024 年、2024-2029 年、2034 年
  • 全球子宮肌瘤治療市場：依國家/地區、績效及預測（2019-2024 年、2024-2029 年及 2034 年）

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章：西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • 子宮肌瘤治療市場：競爭格局
  • 子宮肌瘤治療市場：公司簡介
    • Gynesonics Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Medtronic plc Overview, Products and Services, Strategy and Financial Analysis
    • Boston Scientific Corporation Overview, Products and Services, Strategy and Financial Analysis
    • Karl Storz GmbH Overview, Products and Services, Strategy and Financial Analysis
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章：其他領先和創新企業

  • Abbvie Inc.
  • Richard Wolf GmbH
  • CooperSurgical Inc.
  • Olympus Corporation
  • Myovant Sciences GmbH
  • Insightec Ltd.
  • Hologic Inc.
  • Obseva SA
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Stryker Corporation
  • Smith & Nephew plc
  • Minerva Surgical Inc.
  • Ethicon Inc.
  • Cook Medical LLC

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章：高潛力市場國家、細分市場與策略

  • 2029年子宮肌瘤治療市場：提供新機會的國家
  • 2029年子宮肌瘤治療市場：細分領域帶來新機會
  • 子宮肌瘤治療市場2029年：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第36章 附錄

簡介目錄
Product Code: r24576u

Uterine fibroids treatment encompasses procedures aimed at addressing uterine fibroids, which are non-cancerous growths that form in the uterus, potentially leading to symptoms such as heavy menstrual bleeding, pelvic pain, and pressure on the bladder or bowel.

The primary categories of uterine fibroids treatment consist of subserosal fibroids, intramural fibroids, submucosal fibroids, and pedunculated fibroids. Subserosal fibroids, also known as pedunculated fibroids, are benign growths located on the outer uterine wall, directly connected to the uterus. Various treatment options are available, including hormone therapy, androgens, gonadotropin-releasing hormone antagonists, uterine artery embolization, myomectomy, and hysterectomy. These treatments cater to diverse end-users such as hospitals, ambulatory surgical centers, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The uterine fibroid treatment market research report is one of a series of new reports from The Business Research Company that provides uterine fibroid treatment market statistics, including uterine fibroid treatment industry global market size, regional shares, competitors with a uterine fibroid treatment market share, detailed uterine fibroid treatment market segments, market trends and opportunities, and any further data you may need to thrive in the uterine fibroid treatment industry. This uterine fibroid treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The uterine fibroids treatment market size has grown strongly in recent years. It will grow from $4.06 billion in 2024 to $4.43 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increased incidence of uterine fibroids, advancements in diagnostic techniques, rising awareness and education, impact on quality of life, evolution of minimally invasive procedures.

The uterine fibroids treatment market size is expected to see strong growth in the next few years. It will grow to $6.43 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to advancements in non-invasive treatment, increasing emphasis on fertility preservation, rise in minimally invasive techniques, personalized medicine approaches, collaborative research and development. Major trends in the forecast period include rising focus on fertility-preserving treatments, integration of imaging technologies in treatment planning, increasing awareness and education initiatives, customized treatment plans based on patient profiles, exploration of novel therapeutic targets.

The forecast of 9.8% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. patients by driving up the cost of Magnetic resonance imaging -guided focused ultrasound systems and progesterone modulators sourced from Israel and Canada, exacerbating surgical delays and increasing gynecology department costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated growth in the uterine fibroids treatment market is attributed to the high prevalence of uterine fibroids among women. Uterine fibroids, non-cancerous growths in the uterus, can lead to symptoms such as heavy menstrual bleeding, pelvic pain, and pressure on the bladder or bowel. Uterine fibroids treatment involves blocking estrogen and progesterone production, ceasing menstruation, and improving anemia. For example, a November 2022 report from the National Centre for Biotechnology Information revealed an estimated incidence of uterine fibroids ranging from 40 to 60% among women under 35 and 70 to 80% among women over 50. Thus, the widespread prevalence of uterine fibroids worldwide propels the uterine fibroids treatment market's growth.

The expected rise in healthcare expenditure is set to drive the uterine fibroids treatment market. Healthcare expenditure denotes the total financial resources allocated by a country, government, organization, or individual for healthcare-related goods and services within a specific timeframe. Increased healthcare expenditure supports the development and adoption of advanced uterine fibroids treatment options, including minimally invasive procedures such as uterine artery embolization or magnetic resonance-guided focused ultrasound surgery. For instance, in 2022, Poland's healthcare expenditure reached PLN 205.6 billion ($50.99 billion), representing 6.7% of GDP, a growth of about PLN 36.1 billion ($8.95 billion) from 2021. Hence, the escalating healthcare expenditure contributes to the uterine fibroids treatment market's expansion.

Product innovations are emerging as a significant trend in the uterine fibroid treatment market. Companies in this sector are implementing innovative solutions to maintain their competitive edge. For example, in September 2024, Kissei Pharmaceutical Co., Ltd., a pharmaceutical company based in Japan, launched YSELTY, a new treatment for uterine fibroids that represents a major advancement in women's healthcare. YSELTY provides a non-hormonal treatment option with flexible dosing tailored to individual patient needs, especially for those experiencing severe fibroid symptoms. As a GnRH receptor antagonist, YSELTY works by inhibiting gonadotropin-releasing hormone at its pituitary receptors, thereby reducing estrogen production and effectively alleviating symptoms like bleeding and pain.

Significant players in the uterine fibroids treatment market are directing their efforts toward developing minimally invasive procedures (MIPs) for addressing uterine fibroids. Minimally invasive procedures involve medical interventions or surgeries that cause minimal disruption to the body's normal structure and function. These procedures aim to alleviate symptoms such as heavy menstrual bleeding and pelvic pain while reducing recovery times and preserving reproductive options. As an illustration, Humber River Hospital in Canada launched the use of the Acessa ProVu system in November 2022. This medical technology employs monopolar radiofrequency (RF) energy through a disposable Handpiece for percutaneous, laparoscopic coagulation, and ablation of soft tissue, including the treatment of symptomatic uterine fibroids.

In January 2022, Hologic Inc., a US-based medical technology company, acquired Acessa Health for $80 million, enhancing Hologic's presence in the gynecological surgical space. Acessa Health, a US-based biotechnology company, specializes in developing minimally invasive, uterine-sparing devices designed to treat women suffering from symptomatic fibroids.

Major companies operating in the uterine fibroids treatment market include Gynesonics Inc., Medtronic plc, Boston Scientific Corporation, Karl Storz GmbH, Pfizer Inc., Abbvie Inc., Richard Wolf GmbH, CooperSurgical Inc., Olympus Corporation, Myovant Sciences GmbH, Insightec Ltd., Hologic Inc., Obseva SA, Eli Lilly and Company, GlaxoSmithKline plc, Stryker Corporation, Smith & Nephew plc, Minerva Surgical Inc., Ethicon Inc., Cook Medical LLC, C.R. Bard Inc., Biomerics LLC, Visionsense Corp., Halt Medical Inc., Acessa Health Inc., Blue Endo, LiNA Medical ApS, Merit Medical Systems Inc., Allergan plc, Astellas Pharma Inc.

North America was the largest region in the uterine fibroids treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the uterine fibroids treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the uterine fibroids treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The uterine fibroids treatment market includes revenues earned by entities by providing medical, surgical, and radiologically guided therapies available as treatments for uterine fibroids. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Uterine Fibroids Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on uterine fibroids treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for uterine fibroids treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The uterine fibroids treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Subserosal Fibroids; Intramural Fibroids; Submucosal Fibroids; Pedunculated Fibroids
  • 2) By Treatment Type: Hormone Therapy; Androgens; Gonadotropin-Releasing Hormone Antagonists; Uterine Artery Embolization; Myomectomy; Hysterectomy
  • 3) By End-Users: Hospitals; Ambulatory Surgical Centers; Other End users
  • Subsegments:
  • 1) By Subserosal Fibroids: Pedunculated Subserosal Fibroids; Non-Pedunculated Subserosal Fibroids
  • 2) By Intramural Fibroids: Small Intramural Fibroids; Large Intramural Fibroids
  • 3) By Submucosal Fibroids: Pedunculated Submucosal Fibroids; Non-Pedunculated Submucosal Fibroids
  • 4) By Pedunculated Fibroids: Subserosal Pedunculated Fibroids; Submucosal Pedunculated Fibroids
  • Companies Mentioned: Gynesonics Inc.; Medtronic plc; Boston Scientific Corporation; Karl Storz GmbH; Pfizer Inc.; Abbvie Inc.; Richard Wolf GmbH; CooperSurgical Inc.; Olympus Corporation; Myovant Sciences GmbH; Insightec Ltd.; Hologic Inc.; Obseva SA; Eli Lilly and Company; GlaxoSmithKline plc; Stryker Corporation; Smith & Nephew plc; Minerva Surgical Inc.; Ethicon Inc.; Cook Medical LLC; C.R. Bard Inc.; Biomerics LLC; Visionsense Corp.; Halt Medical Inc.; Acessa Health Inc.; Blue Endo; LiNA Medical ApS; Merit Medical Systems Inc.; Allergan plc; Astellas Pharma Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Uterine Fibroids Treatment Market Characteristics

3. Uterine Fibroids Treatment Market Trends And Strategies

4. Uterine Fibroids Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Uterine Fibroids Treatment Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Uterine Fibroids Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Uterine Fibroids Treatment Market Growth Rate Analysis
  • 5.4. Global Uterine Fibroids Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Uterine Fibroids Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Uterine Fibroids Treatment Total Addressable Market (TAM)

6. Uterine Fibroids Treatment Market Segmentation

  • 6.1. Global Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Subserosal Fibroids
  • Intramural Fibroids
  • Submucosal Fibroids
  • Pedunculated Fibroids
  • 6.2. Global Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hormone Therapy
  • Androgens
  • Gonadotropin-Releasing Hormone Antagonists
  • Uterine Artery Embolization
  • Myomectomy
  • Hysterectomy
  • 6.3. Global Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Ambulatory Surgical Centers
  • Other End users
  • 6.4. Global Uterine Fibroids Treatment Market, Sub-Segmentation Of Subserosal Fibroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Pedunculated Subserosal Fibroids
  • Non-Pedunculated Subserosal Fibroids
  • 6.5. Global Uterine Fibroids Treatment Market, Sub-Segmentation Of Intramural Fibroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Small Intramural Fibroids
  • Large Intramural Fibroids
  • 6.6. Global Uterine Fibroids Treatment Market, Sub-Segmentation Of Submucosal Fibroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Pedunculated Submucosal Fibroids
  • Non-Pedunculated Submucosal Fibroids
  • 6.7. Global Uterine Fibroids Treatment Market, Sub-Segmentation Of Pedunculated Fibroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Subserosal Pedunculated Fibroids
  • Submucosal Pedunculated Fibroids

7. Uterine Fibroids Treatment Market Regional And Country Analysis

  • 7.1. Global Uterine Fibroids Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Uterine Fibroids Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Uterine Fibroids Treatment Market

  • 8.1. Asia-Pacific Uterine Fibroids Treatment Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Uterine Fibroids Treatment Market

  • 9.1. China Uterine Fibroids Treatment Market Overview
  • 9.2. China Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Uterine Fibroids Treatment Market

  • 10.1. India Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Uterine Fibroids Treatment Market

  • 11.1. Japan Uterine Fibroids Treatment Market Overview
  • 11.2. Japan Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Uterine Fibroids Treatment Market

  • 12.1. Australia Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Uterine Fibroids Treatment Market

  • 13.1. Indonesia Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Uterine Fibroids Treatment Market

  • 14.1. South Korea Uterine Fibroids Treatment Market Overview
  • 14.2. South Korea Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Uterine Fibroids Treatment Market

  • 15.1. Western Europe Uterine Fibroids Treatment Market Overview
  • 15.2. Western Europe Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Uterine Fibroids Treatment Market

  • 16.1. UK Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Uterine Fibroids Treatment Market

  • 17.1. Germany Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Uterine Fibroids Treatment Market

  • 18.1. France Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Uterine Fibroids Treatment Market

  • 19.1. Italy Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Uterine Fibroids Treatment Market

  • 20.1. Spain Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Uterine Fibroids Treatment Market

  • 21.1. Eastern Europe Uterine Fibroids Treatment Market Overview
  • 21.2. Eastern Europe Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Uterine Fibroids Treatment Market

  • 22.1. Russia Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Uterine Fibroids Treatment Market

  • 23.1. North America Uterine Fibroids Treatment Market Overview
  • 23.2. North America Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Uterine Fibroids Treatment Market

  • 24.1. USA Uterine Fibroids Treatment Market Overview
  • 24.2. USA Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Uterine Fibroids Treatment Market

  • 25.1. Canada Uterine Fibroids Treatment Market Overview
  • 25.2. Canada Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Uterine Fibroids Treatment Market

  • 26.1. South America Uterine Fibroids Treatment Market Overview
  • 26.2. South America Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Uterine Fibroids Treatment Market

  • 27.1. Brazil Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Uterine Fibroids Treatment Market

  • 28.1. Middle East Uterine Fibroids Treatment Market Overview
  • 28.2. Middle East Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Uterine Fibroids Treatment Market

  • 29.1. Africa Uterine Fibroids Treatment Market Overview
  • 29.2. Africa Uterine Fibroids Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Uterine Fibroids Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Uterine Fibroids Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Uterine Fibroids Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Uterine Fibroids Treatment Market Competitive Landscape
  • 30.2. Uterine Fibroids Treatment Market Company Profiles
    • 30.2.1. Gynesonics Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Medtronic plc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Boston Scientific Corporation Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Karl Storz GmbH Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Uterine Fibroids Treatment Market Other Major And Innovative Companies

  • 31.1. Abbvie Inc.
  • 31.2. Richard Wolf GmbH
  • 31.3. CooperSurgical Inc.
  • 31.4. Olympus Corporation
  • 31.5. Myovant Sciences GmbH
  • 31.6. Insightec Ltd.
  • 31.7. Hologic Inc.
  • 31.8. Obseva SA
  • 31.9. Eli Lilly and Company
  • 31.10. GlaxoSmithKline plc
  • 31.11. Stryker Corporation
  • 31.12. Smith & Nephew plc
  • 31.13. Minerva Surgical Inc.
  • 31.14. Ethicon Inc.
  • 31.15. Cook Medical LLC

32. Global Uterine Fibroids Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Uterine Fibroids Treatment Market

34. Recent Developments In The Uterine Fibroids Treatment Market

35. Uterine Fibroids Treatment Market High Potential Countries, Segments and Strategies

  • 35.1 Uterine Fibroids Treatment Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Uterine Fibroids Treatment Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Uterine Fibroids Treatment Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer